Kamada Ltd, Ness Ziona, Israel, announces the start of phase II testing for the inhaled version of its Alpha-1 Antitrypsin (AAT) treatment for bronchiectasis.
Bronchiectasis is a lung disease caused by mucus blockage causing the distortion of one or more airways. Research estimates there are roughly 100,000 bronchiectasis patients in the United States.
“There is significant potential for the inhaled version of AAT, which is an innovative form of treatment that addresses chronic inflammatory reactions and prevents degeneration of lung function,” says David Tsur, Kamada’s CEO.
Kamada’s inhaled AAT has been designated an orphan drug in both the United States and Europe, granting Kamada various benefits, such as research fund support and tax incentives. If the company’s product is first on the market, this designation will also grant 7 to 12 years of exclusive distribution rights to Kamada.
